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OBJECTIVES: To reduce the increase of the expenditure in disease-modifying drugs
(DMD) used in the first line treatment of remitting-relapsing multiple sclerosis
(RRMS) by forcing a decrease in the price of drugs, as a consequence of the intro-
duction of competition mechanisms. METHODS: By the second half of 2009, the
first biosimilar drug of beta-interferon (bIFN)-1b Betaferon® (Extavia®), gained ac-
cess to the Spanish market, and as a consequence of the acquisition public contest
set up by our hospital, Extavia® was selected, with 7% discount. At that time,
bIFN-1b was used in about 40% of RRMS patients treated in first line. By the end of
2010, the Pharmacy Comitee evaluated the different DMD, taking as starting an
Andalussian Agency for Health Technology Assessment report, and stated that
bIFN-1a sc (44 mg), bIFN-1b and Glatiramer acetate were therateutic equivalents for
the initial treatment of RRMS. An open contest was announced to select the drug to
be used as first line treatment. The lowest therapeutic equivalent daily treatment
cost was selection criterion. All new patients were commenced on the drug se-
lected. A comitee composed by the Medical Manager and the heads of the Neurol-
ogy and the Pharmacy departments assesses the requests for treatment in each
case. The cost difference between the selected treatment and average cost before
the evaluation was multiplied by the total number of new patients to calculate
savings generated. RESULTS: Overall, cost per patient was reduced by 4.5% when
Extavia® was selected as bIFN-1b. When, in a second step, bIFN-1b was designated
as first line drug for RRMS, cost per patient decreased by an additional 7%. A total of
150,000 € (one year) was saved as a result of this strategy. CONCLUSIONS: Thera-
peutic equivalence offers a sound means to improve the efficiency beyond that
obtained with biosimilar drugs, especially in high cost drugs used in chronic ill-
nesses.
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OBJECTIVES: Patients with Alzheimer’s disease (AD) show a high incidence of be-
havioral and psychological symptoms of dementia (BPSD), which often lead to the
prescription of antipsychotics. The objective of the present study was to assess the
impact of the initiation of memantine or cholinesterase inhibitors (ChEIs) on the
use of antipsychotics. METHODS: Patients covered by the Quebec provincial drug
reimbursement program (RAMQ) who had a diagnosis of AD and were initial users
of memantine or ChEIs in the period from January 2005 to March 2011 were se-
lected. The proportion of patients who used antipsychotic drugs was estimated
using prescription data dating back up to 1 year before and up to 1 year after the
first prescription of memantine or ChEIs. For each month in the year before and
after initiation of memantine or ChEIs, the proportion of patients who used an
antipsychotic was estimated. The difference between the slopes corresponding to
the periods pre- and post-memantine or ChEIs were analyzed using an interrupted
time series (ITS) design. RESULTS:Of the random sample of 21,716 patients, 8.9% (n
1,929) initiated memantine whereas 91.1% (n 19,787) initiated a ChEI. The per-
centage of antipsychotics users increased by 118.3% before and by 68.3% after
initiation of a ChEI, and increased by 68.6% before and by 7.0% after initiation of
memantine. According to the ITS analysis, antipsychotics trends pre- and post-
ChEI initiation were not statistically different (P 0.89) while a statistical difference
was observed when comparing the antipsychotics trends pre- and post- meman-
tine initiation (P 0.001). CONCLUSIONS: The initiation of memantine, unlike
ChEIs, has a notable stabilization effect on the prescription of antipsychotics in AD
patients. Given the concerns associated with the use of antipsychotics in AD pa-
tients, initiation of memantine could be considered as a relevant alternative to
alleviate BPSD.
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OBJECTIVES: Examine number of hospitalizations, length of stay and costs among
patients diagnosed with Parkinson’s Disease initiating therapy with either a dopa-
mine agonist (DA) or Rasagiline. METHODS: This study utilized data from the Mar-
ketScan Medicare Supplemental Database from 2/1/2006 through 12/31/2011. Pa-
tients were prescribed Rasagiline or a DA, with first such date identified as index
date, were diagnosed with PD in the 3 years post index date (e.g., the post-period),
had continuous insurance coverage from 6 months prior (e.g., the pre-period)
through the end of the post-period, and were at least 65 years old. The odds or
hospitalization were estimated using logistic regression, while hospital length of
stay (LOS) and number of hospitalizations were estimated using negative binomial
regressions. The costs associated with hospitalizations were estimated from a two
part multivariate model where the first part estimated the probability of being
hospitalized and the second part estimated costs among those hospitalized.
RESULTS: There were 7,230 individuals in the analyses (5,886DA; 1,234 Rasagiline).
The mean age was 76 years and most were male (58.40%), resided in the North
Central (33.71%) or Southern (30.14%) regions of the US and were insured via com-
prehensive (48.42%) or preferred provider organization (36.06%) supplemental in-
surance. After controlling for patient characteristics, general health, disability sta-
tus, comorbid diagnoses, and index prescription characteristics, Rasagiline,
compared to DA, was associated with a significantly lower probability of being
hospitalized in the post-period (OR0.755; 95% CI 0.663 – 0.860), significantly fewer
hospitalizations (-0.21; P0.0001) and shorter LOS (-0.38 days; P0.0001) compared
to individuals who initiated on a DA. Furthermore, total costs associated with
hospitalizations were 24% lower among patients who initiated on Rasagiline
($12,327 v $16,525; P0.0001) compared to initiators on a DA. CONCLUSIONS:
Among patients with PD, initiation with Rasagiline compared to a DA is associated
with significantly improved hospitalization outcomes.
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OBJECTIVES: Qualitative interview aimed to develop a PRO questionnaire that al-
lows assessment of HAE acute attacks. METHODS: Open-ended qualitative inter-
views were performed with HAE patients in Argentina (n10) and the US (n33);
these data were used to develop the first draft questionnaire. Subsequently, more
in-depth qualitative interviews were performed with HAE patients in the UK
(n10), Brazil (n10), Germany (n11) and France (n12). Patients who had expe-
rienced abdominal, cutaneous or laryngeal attacks of varying severity levels were
recruited. Patients initially discussed their experience of HAE attack symptoms,
impacts and treatments in an open-ended manner. Cognitive debriefing of the PRO
was then performed to assess patient understanding and relevance of question-
naire items. RESULTS: Most commonly reported abdominal attack symptoms in-
clude pain, vomiting, stomach swelling, diarrhoea and nausea. Cutaneous attacks
caused skin swelling, pain and redness. Laryngeal attacks led to difficulty breath-
ing, voice change and difficulty swallowing. Patients also discussed attack triggers,
warning signs, impacts and treatment options. Elicited concepts were mapped
onto the PRO, which was revised to include all aspects of importance to HAE pa-
tients. Cognitive debriefing aided in the revision of the questionnaire.
CONCLUSIONS: Data from the qualitative interviews were used to develop an ex-
panded conceptual model capturing all aspects of HAE. The PRO was revised to
ensure all concepts of importance to HAE are captured. The questionnaire can be
considered a valid tool for the long term assessment of the HAE patients.
PND70
PATIENT CHARACTERISTICS AND TREATMENT STATUS IN PARKINSON’S
DISEASE (PD)
Grubb E1, Castelli-Haley J1, Treglia M2, Lage MJ2
1Teva Pharmaceuticals, Kansas City, MO, USA, 2HealthMetrics Outcomes Research, Delray
Beach, FL, USA
OBJECTIVES: Examine patient characteristics and predictors of treatment in U.S.
patients with PD. METHODS: Data were obtained from MarketScan between 1/1/
2006 and 3/30/2011. Selected patients were diagnosed with PD, with initial diagno-
sis date identified as index date. Each subject was at least 35 years old and had
continuous insurance coverage from 6 months prior through 12 months post index
date. Descriptive analysis of patient characteristics compared differences in con-
tinuous variables using t-tests and categorical variables using chi-square statistics.
Logistic regression examined predictors of treatment. The pre-specified level of
statistical significance was 5%. RESULTS: There were 9,423 subjects who met study
criteria. Most (n  5,541, 58.8%) were treated with pharmacotherapy. Treated indi-
viduals were older than untreated (57.1 vs. 56.0 years, p0.0001), more likely to be
male (p0.0035), more likely to reside in the south and less likely to reside in the
northeast (p0.0001). In general, the treated cohort tended to be in poorer health
and have greater disability. The treated were more likely to have been diagnosed by
a neurologist and there were differences in the types of health insurance plans in
which they were enrolled. The logistic analysis examining predictors of treatment
revealed odds ratios (point estimate; 95% CL) for filling a PD prescription were
higher with age (1.03; 1.023 - 1.037), medical ADL (1.349; 1.170 - 1.556) or muscular
skeletal (1.467; 1.329-1.618) disability, prior comorbid disease, diagnosis by a neu-
rologist relative to a GP (1.385; 1.228 – 1.561), and being enrolled in either a POS
(1.524; 1.264 – 1.837) or PPO (1.151; 1.024 – 1.293) health plan. Factors associated with
a lower likelihood of being treated included being female (0.852; 0.780 – 0.930),
region of residence, and higher Charlson Comorbidity Score (0.915; 0.877 – 0.955).
CONCLUSIONS: These analyses highlighted potential age, gender and access dis-
parities in receipt of treatment for PD.
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OBJECTIVES: Examine patient characteristics and predictors of pharmaceutical
treatment class choice among US patients diagnosed with Parkinson’s Disease
(PD).METHODS:This retrospective study utilized data from the MarketScan Claims
and Encounters database over the period from 1/1/2006 through 12/31/2011. Pa-
tients were included in the study if they were diagnosed with PD (with first such
date identified as index date), were at least 35 years old, had continuous insurance
coverage from 6 months prior through 12 months post index date, and received a
post-period prescription a medication for one of the following anti-PD classes:
dopamine agonist (DA), MAO-B inhibitor (MAO-B) or levodopa (LD). The study con-
sisted of descriptive analyses comparing the cohorts and logistic regressions ex-
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